08 Jul New HIV Vaccine Advances in Phase 2 Studies
MedicalResearch.com Interview with:
Dan Barouch, M.D., Ph.D.
Professor of Medicine
Harvard Medical School
Ragon Institute of MGH, MIT, and Harvard
Director, Center for Virology and Vaccine Research
Beth Israel Deaconess Medical Center
Boston, MA 02215
MedicalResearch.com: What is the background for this study? What are the main findings?
Response: This study demonstrates that the mosaic Ad26/Env HIV vaccine candidate induced robust and comparable immune responses in humans and monkeys.
Moreover, the vaccine provided 67% protection against viral challenge in monkeys.
MedicalResearch.com: What recommendations do you have for future research as a result of this work?
Response: Based on these data, the mosaic Ad26/Env HIV-1 vaccine has been advanced into a phase 2b clinical efficacy study to determine whether this vaccine will prevent HIV infection in humans in southern Africa (results are expected in 2021-2022). This is only the 5th HIV vaccine concept that will be tested for efficacy in humans in the 35+ year history of the global HIV epidemic.
Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a
Barouch, Dan H et al.
The Lancet , Volume 0 , Issue 0 ,
The information on MedicalResearch.com is provided for educational purposes only, and is in no way intended to diagnose, cure, or treat any medical or other condition. Always seek the advice of your physician or other qualified health and ask your doctor any questions you may have regarding a medical condition. In addition to all other limitations and disclaimers in this agreement, service provider and its third party providers disclaim any liability or loss in connection with the content provided on this website.